Floatz logo

Karenitecin

Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.Phase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

525 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
TIL
Inge Marie Svane
Phase 2BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB
Carboplatin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Karenitecin is also rated in:

neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
melanomaDormant
B
Indicative ·
61 / 100
View asset →
primary peritoneal carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →